0001209191-23-005349.txt : 20230127 0001209191-23-005349.hdr.sgml : 20230127 20230127181835 ACCESSION NUMBER: 0001209191-23-005349 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20221114 FILED AS OF DATE: 20230127 DATE AS OF CHANGE: 20230127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Neuman Linda L CENTRAL INDEX KEY: 0001951205 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 23564706 MAIL ADDRESS: STREET 1: C/O AEGLEA BIOTHERAPEUTICS, INC. STREET 2: 805 LAS CIMAS PARKWAY, SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78746 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aeglea BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 805 LAS CIMAS PARKWAY STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: (512) 942-2935 MAIL ADDRESS: STREET 1: 805 LAS CIMAS PARKWAY STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78746 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2022-11-14 0 0001636282 Aeglea BioTherapeutics, Inc. AGLE 0001951205 Neuman Linda L C/O AEGLEA BIOTHERAPEUTICS, INC. 805 LAS CIMAS PARKWAY, SUITE 100 AUSTIN TX 78746 0 1 0 0 Chief Medical Officer Common Stock 4000 D Employee Stock Option (right to buy) 7.82 2031-04-22 Common Stock 40000 D Employee Stock Option (right to buy) 3.17 2032-02-16 Common Stock 30000 D Employee Stock Option (right to buy) 1.90 2032-04-14 Common Stock 25000 D Employee Stock Option (right to buy) 0.68 2032-08-22 Common Stock 41250 D The options will vest as to 1/4th of the total shares on April 12, 2022, and then 1/48th of the shares will vest monthly thereafter, such that the option is fully vested on April 12, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The stock option vests and becomes exercisable in 48 equal monthly installments beginning on May 15, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The stock option vests and becomes exercisable in 48 equal monthly installments beginning on September 23, 2022 until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors, the stock option will vest as to 80% of the award by January 1, 2023, and 1/48th of the stock option will vest and become exercisable monthly thereafter until such time as the option is 100% vested. Exhibit 24 - Power of Attorney /s/ James Kastenmayer, by power of attorney 2023-01-27 EX-24 2 poa.txt POA DOCUMENT POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Jonathan Alspaugh and James Kastenmayer, and each of them, as true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a representative of Aeglea BioTherapeutics, Inc. (the "Company"), any and all Form ID, or Form 3, 4 or 5 reports and any amendments thereto required to be filed by the undersigned in accordance with Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and the rules thereunder with respect to transactions in the Company's securities; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, or Form 3, 4 or 5 report and any amendments thereto and timely file such report with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his or her discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary, and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that no such attorney-in-fact, in serving in such capacity at the request of the undersigned, is hereby assuming, nor is the Company hereby assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Form 3, 4 or 5 reports with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. N WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 13th day of October, 2022. /s/ Linda Neuman Name: Linda Neuman